This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nature's Sunshine Products Names Dr. Matthew Tripp As Chief Scientific Officer

LEHI, Utah, April 23, 2013 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (Nasdaq:NATR), a leading natural health and wellness company engaged in the manufacture and direct selling of nutritional and personal care products, today announced the appointment of Matthew Tripp, Ph.D., as Chief Scientific Officer. Dr. Tripp has extensive senior level R&D experience in consumer product manufacturing for major consumer goods companies, and will play a significant role in the development, manufacturing and quality control of Nature's Sunshine Product's broad range of nutritional products.

Since 2000, Dr. Tripp has served as Vice President, Research and Development, at Metagenics, a leading developer, manufacturer and distributor of high quality dietary supplements and medical foods sold through health care practitioners in the U.S. and pharmacies abroad. He has also concurrently served as Senior Vice President, Research and Development, at KinDex Therapeutics, a biotechnology company created by Metagenics. At Metagenics, he had direct responsibility for managing the discovery, development, safety, and clinical validation of medical foods and nutraceuticals. He played the leadership role of installing a new product development process that accelerated time to market and the volume of science based, clinically tested new products moving through the product pipeline. Significantly, Dr. Tripp led the creation of a substantial body of proprietary intellectual property, resulting in over 100 patents and patent applications.

Prior to working at Metagenics, he worked in progressively more responsible R&D and leadership roles at the Kellogg Company and Miller Brewing Company. Dr. Tripp received his Ph.D. from Washington State University in Physiology/Microbial Genetics/Microbiology; an M.A. in Microbial Physiology/Bacterial Genetics and a B.S. in Biology both from Western Michigan University. He also completed extensive post-doctoral research at the University of California – San Diego where he discovered novel protein phosphorylation cascades involved in nutrient signaling (nutrigenomics) – processes that when disrupted by poor diet, lead to metabolic disease and chronic illness.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,596.35 -350.33 -1.95%
S&P 500 2,057.64 -43.85 -2.09%
NASDAQ 4,958.4680 -122.0370 -2.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs